Clinical trials: Liver Transplant Infection
Liver Transplantation
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
The study aimed to present our experience in treating recurrent HCV genotype 4 infection post living donor liver transplantation (LDLT) since introduction of the second generation direct acting antiviral drugs (DAAs) in Egypt.
- Trial name
- NCT03133065
- Testing
- treatment of HCV with oral direct acting antiviral therapy
- Volunteers
- 89 people
- Sponsor
- Ain Shams University
Post-transplant Hepatitis C
Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C
This is a single arm, open-label study which will be opened at specific clinical sites at the request of an investigator for the treatment of individual subjects for whom there are no other treatment options.
- Trial name
- NCT01779518
- Testing
- Sofosbuvir, Ribavirin, Pegylated Interferon
- Sponsor
- Gilead Sciences
HIV Infections, Hepatitis C
Liver Transplantation in Patients With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Coinfection
To show the feasibility of liver transplantation in HCV-HIV coinfected patients. To study the two-year survival after transplantation, the interaction between HCV and HIV after transplantation, the influence of HIV on HCV…
- Trial name
- NCT00158535
- Testing
- liver transplantation
- Where
- France
- Volunteers
- 15 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Recurrent Hepatitis C
Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection
This study will assess the efficacy of everolimus as an inhibitor of fibrosis progression in liver transplant patients who have a recurrence of hepatitis C viral infection in the transplant
- Trial name
- REVERT (NCT00582738)
- Testing
- CsA-TAC (standard Treatment), Everolimus
- Where
- Argentina
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B Virus, Liver Transplant
To Evaluate the Efficacy and Safety of Tenofovir Alafenamide Conversion in Liver Transplant Patients
This clinical trial aims to confirm the efficacy and safety of Vemlia® tablets (Tenofovir alafenamide) in liver transplant patients with hepatitis B, focusing on their effects on renal function.
- Conditions
- Hepatitis B Virus, Liver Transplant, Renal Insufficiency
- Trial name
- NCT06589518
- Testing
- Tenofovir Alafenamide Citrate
- Volunteers
- 108 people
- Sponsor
- Jongman Kim
Liver Transplant Infection
Application of Nanopore Adaptive Sequencing
Infection post liver transplantation is an important factor in the death in patients. The traditional method of diagnosing infection post liver transplantation is laboratory tests.
- Trial name
- NCT06542042
- Testing
- NAS, NGS and Laboratory tests
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Third People's Hospital
Haemopoietic Stem Cell Transplantation, Allograft
Impact of a Fourth Hexavalent Vaccine After Hematopoietic Stem Cell Transplantation
It is recommended for patients who underwent an hematopoietic stem cell transplantation to receive 6 months after the graft 3 injections of hexavalent vaccine (diphteria-tetanus- poliomyelitis-pertussis-Hib-HBV) within 2 months…
- Trial name
- EVaxAll (NCT03402776)
- Testing
- 4th dose of hexavalent vaccine 1 month after the 3rd dose
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Grenoble
Renal Failure, Hyponatremia
Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation
The aim of this study is to evaluate the effect of prolonged administration of albumin and midodrine on the prevention of complications (renal failure, sepsis, hemorrhage, hepatic encephalopathy and hyponatremia) in patients with…
- Conditions
- Renal Failure, Hyponatremia, Sepsis, Hepatic Encephalopathy
- Trial name
- MACHT (NCT00839358)
- Testing
- albumin, Midodrine
- Where
- Spain
- Volunteers
- 199 people
- Sponsor
- Hospital Clinic of Barcelona
Hepatitis C
Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation.
The purpose of this study was to evaluate the efficacy (and safety) of antiviral therapy in patients with chronic hepatitis C after liver transplantation.
- Trial name
- NCT00383864
- Testing
- Pegylated interferon and ribavirin
- Where
- Spain
- Volunteers
- 55 people
- Sponsor
- Hospital Clinic of Barcelona
Hepatitis C Virus Infection
Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
The primary objectives of the study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (Vosevi®; SOF/VEL/VOX) fixed-dose combination (FDC) for 12 weeks and of…
- Trial name
- POLARIS-4 (NCT02639247)
- Testing
- SOF/VEL/VOX, SOF/VEL
- Where
- 78 sites in United States, Australia and 6 more
- Volunteers
- 333 people
- Sponsor
- Gilead Sciences
Liver Transplant, Fungal Infection
An Assessment of Voriconazole Pharmacokinetics and Pharmacogenetics in Liver Transplant Recipients - Pilot Study
A fixed-dosing regimen of voriconazole is routinely used as prophylaxis against aspergillosis in liver transplant patients admitted to the transplant intensive care unit at UPMC.
- Trial name
- NCT00371605
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Pittsburgh
Hepatitis C, Chronic
PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.
This 2-arm study was designed to evaluate the efficacy, safety, and tolerability of prophylactic PEGASYS plus COPEGUS after liver transplantation for hepatitis C, compared to initiation of antiviral therapy at the time of…
- Trial name
- NCT00087633
- Testing
- peginterferon alfa-2a [Pegasys], Copegus
- Where
- 28 sites in United States
- Volunteers
- 115 people
- Sponsor
- Hoffmann-La Roche
Liver Disease
Randomized Controlled Trial of ImmuKnow in Liver Transplantation
ImmuKnow detects cell-mediated immunity in solid-organ transplant recipients undergoing immunosuppressive therapy. Increasing ImmuKnow values indicate a decrease of immunosuppression and decreasing ImmuKnow values suggest an…
- Trial name
- NCT01764581
- Testing
- Tacrolimus regulation according to ImmuKnow values
- Volunteers
- 206 people
- Sponsor
- University of Bologna
Hepatitis C
Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies
The objective of this observational study is to characterize long-term (5 years post event) clinical outcomes in patients who experienced a thromboembolic event (TEE) during participation in the GSK ENABLE clinical trials.
- Trial name
- NCT01715779
- Testing
- Eltrombopag
- Volunteers
- 22 people
- Sponsor
- Novartis
Hepatitis B
PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients
Open-label pharmacokinetic drug interaction study.
- Trial name
- NCT00644761
- Testing
- Adefovir Dipivoxil
- Where
- 11 sites in United States
- Volunteers
- 16 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus Infection, Liver Transplantation
Effect of Immunosuppression Drug Weaning on Hepatitis C Virus (HCV)-Induced Liver Damage After Liver Transplantation
Viral infections can profoundly influence alloimmune responses and hamper allograft tolerance induction. Persistent hepatitis C virus (HCV) infection occurs in 50% of liver and 20% of kidney transplant recipients, but the impact…
- Trial name
- NCT00668369
- Testing
- Gradual immunosuppression drug withdrawal.
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- Hospital Clinic of Barcelona
Liver Transplant Infection
Impact of a TDM-guided ECPA Program for Optimizing Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam-based Regimen
Previous studies have clearly demonstrated a significant impact of optimised antibiotic therapy based on a TDM-guided approach in reducing the clinical and microbiological failure rate and in improving the achievement of an…
- Trial name
- NCT06718517
- Where
- Italy
- Volunteers
- 65 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Cytomegalovirus Infections
Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients
The purpose of this research study is to investigate whether or not oral maribavir is safe and effective compared to oral ganciclovir for preventing CMV disease when administered for up to 14 weeks in patients who have had a…
- Trial name
- NCT00497796
- Testing
- maribavir, ganciclovir
- Where
- 55 sites in United States
- Volunteers
- 307 people
- Sponsor
- Shire
GVHD - Graft-Versus-Host Disease, Infections After HSCT
Cell Free DNA Profiling As a Tool to Monitor Clinically-Relevant Events in Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is a life-saving treatment for people with severe blood-related diseases.
- Conditions
- GVHD - Graft-Versus-Host Disease, Infections After HSCT, Transplant Associated Microangiopathy TAM, Sinusoidal Obstruction Syndrome (SOS)
- Trial name
- NCT06715046
- Testing
- Sample collation for cfDNA methylation analysis, Sample collection for EV phenotype analysis
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- University of Turin, Italy